Table 1

Univariate analysis of factors associated with response to daptomycin

CharacteristicValue for patients with daptomycin therapy outcomeaP value
Success (n = 65)Failure (n = 15)
Age of ≥66 yr38 (58)10 (67)0.559
Male gender34 (52)9 (60)0.590
Weight (kg)73 (61–92)80 (69–86)0.693
Location 2 days before daptomycin therapy
    Community19 (29)2 (13)0.207
    Hospital37 (57)12 (80)0.098
    Nursing home/extended care facility9 (14)1 (7)0.449
Stay in ICU (anytime during daptomycin treatment)21 (32)8 (53)0.127
Comorbid conditions
    Acute coronary syndromes4 (6)1 (7)0.941
    Congestive heart failure13 (20)3 (20)1.000
    Anemia/hematologic diseases7 (11)2 (13)0.777
    Liver disease1 (2)1 (7)0.252
    Chronic obstructive pulmonary disease (COPD)8 (12)2 (13)0.914
    Acute renal failure13 (20)3 (20)1.000
    Neurologic disease5 (8)3 (20)0.152
    Diabetes mellitus26 (40)4 (27)0.336
    T-cell-mediated immunity
        Cancer (hematologic)4 (6)1 (7)0.941
        Cancer (solid organ)10 (15)2 (13)0.841
        HIV positive1 (2)00.629
        Transplant recipient1 (2)00.629
    Peripheral vascular disease4 (6)2 (13)0.341
    Sepsis/septicemia5 (8)1 (7)0.892
    Renal insufficiency
        Mild (CLCR of 30 to 50 ml/min)34 (52)2 (13)0.006
        Moderate (CLCR of <30 ml/min, no dialysis)31 (48)13 (87)
Other characteristics
    Prior antibiotics for S. aureus bloodstream infection (BSI)51 (78)14 (93)0.183
    Prior vancomycin for S. aureus BSI35 (54)12 (80)0.232
        Prior vancomycin failure15 (23)7 (47)0.065
    MRSA45 (69)11 (73)0.755
Initial daptomycin dose (mg/kg)6 (6–6)6 (4–6)0.447
Final daptomycin dose (mg/kg)6 (6–6)6 (5–6)0.430
Duration of daptomycin treatment (days)14 (8–34)7 (3–9)0.006
  • a Data are numbers (%) of patients or medians (interquartile ranges).